Updated overall survival outcomes in ENZAMET (ANZUP 1304), an international, cooperative group trial of enzalutamide in metastatic hormone-sensitive prostate cancer

Prof. Davis elaborates on the ENZAMET trial, the design and updated results of this trial, as well as the overall survival benefit in mHSPC with the addition of enzalutamide.